In vitro and in vivo antiviral activity and resistance profile of ombitasvir, an inhibitor of hepatitis C virus NS5A

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 2, 2015, Pages 979-987

  Krishnan, Preethi ^a   Beyer, Jill ^a   Mistry, Neeta ^a   Koev, Gennadiy ^a   Reisch, Thomas ^a   DeGoey, David ^a   Kati, Warren ^a   Campbell, Andrew ^a   Williams, Laura ^a   Xie, Wangang ^a   Setze, Carolyn ^a   Molla, Akhteruzzaman ^a   Collins, Christine ^a   Pilot Matias, Tami ^a  

^a ABBVIE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NONSTRUCTURAL PROTEIN 5A; OMBITASVIR; PLACEBO; VIRUS RNA; ABT-267; ANILIDE; ANTIVIRUS AGENT; CARBAMIC ACID DERIVATIVE;

AMINO ACID SUBSTITUTION; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG HALF LIFE; DRUG TOLERABILITY; EC50; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 5; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; PLASMA PROTEIN BINDING; PRIORITY JOURNAL; REPLICON; VIRUS LOAD; CELL LINE; DRUG EFFECTS; HEPACIVIRUS;

ANILIDES; ANTIVIRAL AGENTS; CARBAMATES; CELL LINE; DRUG RESISTANCE, VIRAL; HEPACIVIRUS; HEPATITIS C; HUMANS;

EID: 84921898327     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.04226-14     Document Type: Article

References (45)

1. Lavanchy D. 2011. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect 17:107-115. http://dx.doi.org/10.1111/j.1469-0691.2010 .03432.x.
2. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. 2013. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 57:1333-1342. http://dx .doi.org/10.1002/hep.26141.
3. Smith DB, Bukh J, Kuiken C, Muerhoff AS, Rice CM, Stapleton JT, Simmonds P. 2014. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment Web resource. Hepatology 59:318-327. http://dx.doi.org/10.1002/hep .26744.
4. Blatt LM, Mutchnick MG, Tong MJ, Klion FM, Lebovics E, Freilich B, Bach N, Smith C, Herrera J, Tobias H, Conrad A, Schmid P, McHutchison JG. 2000. Assessment of hepatitis C virus RNA and genotype from 6807 patients with chronic hepatitis C in the United States. J Viral Hepat 7:196-202. http://dx.doi.org/10.1046/j.1365-2893.2000.00221.x.
5. Zein NN. 2000. Clinical significance of hepatitis C virus genotypes. Clin Microbiol Rev 13:223-235. http://dx.doi.org/10.1128/CMR.13.2.223-235 .2000.
6. Toyoda H, Kumada T, Takaguchi K, Shimada N, Tanaka J. 2014. Changes in hepatitis C virus genotype distribution in Japan. Epidemiol Infect 142:2624-2628. http://dx.doi.org/10.1017/S0950268814000478.
7. Zein NN, Persing DH. 1996. Hepatitis C genotypes: current trends and future implications. Mayo Clin Proc 71:458-462. http://dx.doi.org/10 .4065/71.5.458.
8. Nousbaum JB. 1998. Genomic subtypes of hepatitis C virus: epidemiology, diagnosis and clinical consequences. Bull Soc Pathol Exot 91:29-33.
9. Adams NJ, Chamberlain RW, Taylor LA, Davidson F, Lin CK, Elliott RM, Simmonds P. 1997. Complete coding sequence of hepatitis C virus genotype 6a. Biochem Biophys Res Commun 234:393-396. http://dx.doi .org/10.1006/bbrc.1997.6627.
10. Chamberlain RW, Adams N, Saeed AA, Simmonds P, Elliott RM. 1997. Complete nucleotide sequence of a type 4 hepatitis C virus variant, the predominant genotype in the Middle East. J Gen Virol 78:1341-1347.
11. Chamberlain RW, Adams NJ, Taylor LA, Simmonds P, Elliott RM. 1997. The complete coding sequence of hepatitis C virus genotype 5a, the predominant genotype in South Africa. Biochem Biophys Res Commun 236:44-49. http://dx.doi.org/10.1006/bbrc.1997.6902.
12. Simmonds P. 2004. Genetic diversity and evolution of hepatitis C virus-15 years on. J Gen Virol 85:3173-3188. http://dx.doi.org/10.1099/vir .0.80401-0.
13. Guedj J, Dahari H, Rong L, Sansone ND, Nettles RE, Cotler SJ, Layden TJ, Uprichard SL, Perelson AS. 2013. Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life. Proc Natl Acad Sci U S A 110:3991-3996. http://dx.doi.org/10.1073/pnas.1203110110.
14. Pawlotsky JM. 2012. The science of direct-acting antiviral and hosttargeted agent therapy. Antivir Ther 17:1109-1117. http://dx.doi.org/10 .3851/IMP2423.
15. Pawlotsky JM. 2014. New hepatitis C therapies: the toolbox, strategies, and challenges. Gastroenterology 146:1176-1192. http://dx.doi.org/10 .1053/j.gastro.2014.03.003.
16. Jacobson IM, Pawlotsky JM, Afdhal NH, Dusheiko GM, Forns X, Jensen DM, Poordad F, Schulz J. 2012. A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C. J Viral Hepat 19(Suppl 2):S1-S26. http://dx.doi.org/10.1111/j.1365-2893.2012.01590.x.
17. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, Muir AJ, Ferenci P, Flisiak R, George J, Rizzetto M, Shouval D, Sola R, Terg RA, Yoshida EM, Adda N, Bengtsson L, Sankoh AJ, Kieffer TL, George S, Kauffman RS, Zeuzem S. 2011. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 364:2405-2416. http://dx.doi.org/10.1056/NEJMoa1012912.
18. Jacobson I, Dore G, Foster G, Fried M, Radu M, Rafalskiy V, Moroz I, Craxi A, Peeters M, Lenz O, Ouwerkerk-Mahadevan S, Kalmeijer R, Beumont-Mauviel M. 2013. Simeprevir (TMC435) with peginterferon/ ribavirin for chronic HCV genotype-1 infection in treatment-naive parients: results from QUEST-1, a phase III trial. J Hepatol 58:S574. http://dx .doi.org/10.1016/S0168-8278(13)61424-5.
19. Manns M, Marcellin P, Poordad F, Stanislau Affonso de Araujo E, Buti M, Horsmans Y, Janczewska E, Villamil F, Peeters M, Lenz O, Ou-werkerk-Mahadevan S, Kalmeijer R, Beumont-Mauviel M. 2013. Simeprevir (TMC435) with perinterferon/ribavirin for treatment of chronic HCV genotype-1 infection in treatment-naive patients: results from QUEST-2, a phase III trial. J Hepatol 58:S568. http://dx.doi.org/10 .1016/S0168-8278(13)61413-0.
20. Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, Schultz M, Davis MN, Kayali Z, Reddy KR, Jacobson IM, Kowdley KV, Nyberg L, Subramanian GM, Hyland RH, Arterburn S, Jiang D, McNally J, Brainard D, Symonds WT, McHutchison JG, Sheikh AM, Younossi Z, Gane EJ. 2013. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 368:1878-1887. http: //dx.doi.org/10.1056/NEJMoa1214853.
21. Tellinghuisen TL, Foss KL, Treadaway J. 2008. Regulation of hepatitis C virion production via phosphorylation of the NS5A protein. PLoS Pathog 4:e1000032. http://dx.doi.org/10.1371/journal.ppat.1000032.
22. Macdonald A, Harris M. 2004. Hepatitis C virus NS5A: tales of a promiscuous protein. J Gen Virol 85:2485-2502. http://dx.doi.org/10.1099/vir.0 .80204-0.
23. Huang L, Hwang J, Sharma SD, Hargittai MR, Chen Y, Arnold JJ, Raney KD, Cameron CE. 2005. Hepatitis C virus nonstructural protein 5A (NS5A) is an RNA-binding protein. J Biol Chem 280:36417-36428. http://dx.doi.org/10.1074/jbc.M508175200.
24. Hughes M, Griffin S, Harris M. 2009. Domain III of NS5A contributes to both RNA replication and assembly of hepatitis C virus particles. J Gen Virol 90:1329-1334. http://dx.doi.org/10.1099/vir.0.009332-0.
25. Pawlotsky JM. 2013. NS5A inhibitors in the treatment of hepatitis C. J Hepatol 59:375-382. http://dx.doi.org/10.1016/j.jhep.2013.03.030.
26. Krueger AC, Madigan DL, Beno DW, Betebenner DA, Carrick R, Green BE, He W, Liu D, Maring CJ, McDaniel KF, Mo H, Molla A, Motter CE, Pilot-Matias TJ, Tufano MD, Kempf DJ. 2012. Novel hepatitis C virus replicon inhibitors: synthesis and structure-activity relationships of fused pyrimidine derivatives. Bioorg Med Chem Lett 22:2212-2215. http://dx .doi.org/10.1016/j.bmcl.2012.01.096.
27. DeGoey DA, Grampovnik DJ, Liu D, Pratt JK, Krishnan P, Pilot-Matias TJ, Marsh KC, Molla A, Kempf DJ, Maring CJ. 2013. Discovery of pyrido[2,3-d]pyrimidine-based inhibitors of HCV NS5A. Bioorg Med Chem Lett 23:3627-3630. http://dx.doi.org/10.1016/j.bmcl.2013.04.009.
28. DeGoey DA, Randolph JT, Liu D, Pratt J, Hutchins C, Donner P, Krueger AC, Matulenko M, Patel S, Motter CE, Nelson L, Keddy R, Tufano M, Caspi DD, Krishnan P, Mistry N, Koev G, Reisch TJ, Mondal R, Pilot-Matias T, Gao Y, Beno DW, Maring CJ, Molla A, Dumas E, Campbell A, Williams L, Collins C, Wagner R, Kati WM. 2014. Discovery of ABT-267, a pan-genotypic inhibitor of HCV NS5A. J Med Chem 57:2047-2057. http://dx.doi.org/10.1021/jm401398x.
29. Pilot-Matias T, Tripathi R, Cohen D, Gaultier I, Dekhtyar T, Lu L, Reisch T, Irvin M, Hopkins T, Pithawalla R, Middleton T, Ng T, McDaniel K, Or YS, Menon R, Kempf D, Molla A, Collins C. 2015. In vitro and in vivo antiviral activity and resistance profile of the hepatitis C virus NS3/4A protease inhibitor ABT-450. Antimicrob Agents Chemother 59:988-997. http://dx.doi.org/10.1128/AAC.04227-14.
30. Feld JJ, Kowdley KV, Coakley E, Sigal S, Nelson DR, Crawford D, Weiland O, Aguilar H, Xiong J, Pilot-Matias T, DaSilva-Tillmann B, Larsen L, Podsadecki T, Bernstein B. 2014. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 370: 1594-1603. http://dx.doi.org/10.1056/NEJMoa1315722.
31. Ferenci P, Bernstein D, Lalezari J, Cohen D, Luo Y, Cooper C, Tam E, Marinho RT, Tsai N, Nyberg A, Box TD, Younes Z, Enayati P, Green S, Baruch Y, Bhandari BR, Caruntu FA, Sepe T, Chulanov V, Janczewska E, Rizzardini G, Gervain J, Planas R, Moreno C, Hassanein T, Xie W, King M, Podsadecki T, Reddy KR. 2014. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med 370:1983-1992. http://dx.doi.org/10.1056/NEJMoa1402338.
32. Poordad F, Hezode C, Trinh R, Kowdley KV, Zeuzem S, Agarwal K, Shiffman ML, Wedemeyer H, Berg T, Yoshida EM, Forns X, Lovell SS, Da Silva-Tillmann B, Collins CA, Campbell AL, Podsadecki T, Bernstein B. 2014. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 370:1973-1982. http://dx.doi.org /10.1056/NEJMoa1402869.
33. Zeuzem S, Jacobson IM, Baykal T, Marinho RT, Poordad F, Bourliere M, Sulkowski MS, Wedemeyer H, Tam E, Desmond P, Jensen DM, Di Bisceglie AM, Varunok P, Hassanein T, Xiong J, Pilot-Matias T, DaSilva-Tillmann B, Larsen L, Podsadecki T, Bernstein B. 2014. Retreatment of HCVwith ABT-450/r-ombitasvir and dasabuvir with ribavirin.NEngl J Med 370:1604-1614. http://dx.doi.org/10.1056/NEJMoa1401561.
34. Andreone P, Colombo MG, Enejosa JV, Koksal I, Ferenci P, Maieron A, Müllhaupt B, Horsmans Y, Weiland O, Reesink HW, Rodrigues L, Hu YB, Podsadecki T, Bernstein B. 9 May 2014. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients withHCVgenotype 1b infection. Gastroenterology http://dx.doi.org/10.1053/j.gastro.2014.04.045.
35. Halfman CJ. 1981. Concentrations of binding protein and labeled analyte that are appropriate for measuring at any analyte concentration range in radioimmunoassays. Methods Enzymol 74:481-497. http://dx.doi.org/10 .1016/0076-6879(81)74034-5.
36. Kato T, Date T, Miyamoto M, Furusaka A, Tokushige K, Mizokami M, Wakita T. 2003. Efficient replication of the genotype 2a hepatitis C virus subgenomic replicon. Gastroenterology 125:1808-1817. http://dx.doi.org /10.1053/j.gastro.2003.09.023.
37. Hopkins S, Scorneaux B, Huang Z, Murray MG, Wring S, Smitley C, Harris R, Erdmann F, Fisher G, Ribeill Y. 2010. A novel nonimmunosuppressive analog of cyclosporin a that exhibits potent inhibition of hepatitis C virus RNA replication in vitro. Antimicrob Agents Chemother 54:660-672. http://dx.doi.org/10.1128/AAC.00660-09.
38. Tripathi RL, Krishnan P, He Y, Middleton T, Pilot-Matias T, Chen CM, Lau DT, Lemon SM, Mo H, Kati W, Molla A. 2007. Replication efficiency of chimeric replicon containing NS5A-5B genes derived from HCV-infected patient sera. Antiviral Res 73:40-49. http://dx.doi.org/10 .1016/j.antiviral.2006.07.005.
39. Mo H, Lu L, Pilot-Matias T, Pithawalla R, Mondal R, Masse S, Dekhtyar T, Ng T, Koev G, Stoll V, Stewart KD, Pratt J, Donner P, Rockway T, Maring C, Molla A. 2005. Mutations conferring resistance to a hepatitis C virus (HCV) RNA-dependent RNA polymerase inhibitor alone or in combination with an HCV serine protease inhibitor in vitro. Antimicrob Agents Chemother 49:4305-4314. http://dx.doi.org/10.1128/AAC .49.10.4305-4314.2005.
40. Lawitz E, Marbury T, Campbell A, Dumas E, Pilot-Matias T, Krishnan P, Setze S, Wangang X, Podsadecki T, Bernstein B, Williams L. 2012. Safety and antiviral activity of ABT-267, a novel NS5A inhibitor, during 3-day monotherapy: first study in HCV genotype-1 (GT1)-infected treat-ment-naive subjects. J Hepatol 56:S469-S470. http://dx.doi.org/10.1016 /S0168-8278(12)61198-2.
41. Combet C, Garnier N, Charavay C, Grando D, Crisan D, Lopez J, Dehne-Garcia A, Geourjon C, Bettler E, Hulo C, Le Mercier P, Bartenschlager R, Diepolder H, Moradpour D, Pawlotsky JM, Rice CM, Trepo C, Penin F, Deleage G. 2007. euHCVdb: the European hepatitis C virus database. Nucleic Acids Res 35:D363-D366. http://dx.doi.org/10.1093 /nar/gkl970.
42. Scheel TK, Gottwein JM, Mikkelsen LS, Jensen TB, Bukh J. 2011. Recombinant HCV variants with NS5A from genotypes 1-7 have different sensitivities to an NS5A inhibitor but not interferon-alpha. Gastroenterology 140:1032-1042. http://dx.doi.org/10.1053/j.gastro.2010.11.036.
43. McCarville J, Seifer M, Standring D, Mayers D. 2013. Treatment-emergent variants following 3 days of monotherapy with IDX719, a potent, pangenotypic NS5A inhibitor, in subjects infected with HCV genotypes 1-4. J Hepatol 58:S491-S492. http://dx.doi.org/10.1016/S0168-8278(13)61210-6.
44. Fridell RA, Qiu D, Wang C, Valera L, Gao M. 2010. Resistance analysis of the hepatitisCvirus NS5A inhibitor BMS-790052 in an in vitro replicon system. Antimicrob Agents Chemother 54:3641-3650. http://dx.doi.org /10.1128/AAC.00556-10.
45. Wong KA, Worth A, Martin R, Svarovskaia E, Brainard DM, Lawitz E, Miller MD, Mo H. 2013. Characterization of hepatitis C virus resistance from a multiple-dose clinical trial of the novel NS5A inhibitor GS-5885. Antimicrob Agents Chemother 57:6333-6340. http://dx.doi.org/10.1128 /AAC.02193-12.